GFM
FDMT icon

GF Fund Management’s 4D Molecular Therapeutics FDMT Stock Holding History

GF Fund Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
1,082
-193
-15% -$1.88K ﹤0.01% 510
2026
Q1 		$11.9K Buy
1,275
+153
+14% +$1.33K ﹤0.01% 545
2025
Q4 		$8.41K Buy
1,122
+117
+12% +$1.19K ﹤0.01% 592
2025
Q3 		$8.73K Sell
1,005
-142
-12% -$849 ﹤0.01% 566
2025
Q2 		$4.25K Hold
1,147
– – ﹤0.01% 635
2025
Q1 		$3.71K Buy
1,147
+176
+18% +$829 ﹤0.01% 633
2024
Q4 		$5.41K Buy
+971
New +$7.62K ﹤0.01% 608

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

GF Fund Management's FDMT Position: Q2 2026 in Review

GF Fund Management reduced its 4D Molecular Therapeutics (FDMT) stake by 15% in Q2 2026, selling an estimated $1.88K and leaving 1,082 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #510.

GF Fund Management first reported a position in FDMT in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • GF Fund Management held 1,082 shares of 4D Molecular Therapeutics worth $14.4K as of Q2 2026.
  • GF Fund Management sold 193 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.88K.
  • 4D Molecular Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #510 holding.
  • GF Fund Management first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.